home / stock / tnya / tnya articles
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company w...
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares rose 95.5% to $15.80 in pre-market trading after the company inked a deal with Kyowa Kirin...
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual S...
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company w...
News, Short Squeeze, Breakout and More Instantly...
Tenaya Therapeutics Inc. Company Name:
TNYA Stock Symbol:
NASDAQ Market:
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role Pediatric Cardiologist and Genetic Therapy Expert Barry J. Byrne, M.D., Ph.D., Joins Scientific Advisory Board Board Member Jin-Long Chen, Ph.D., Steps Down ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that ...
2024-06-10 07:30:04 ET William Blair analyst issues OUTPERFORM recommendation for TNYA on June 10, 2024 05:41AM ET. TNYA was trading at $3.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recomm...